Vor Biopharma (VOR) Competitors $2.10 +0.03 (+1.45%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock VOR vs. PHVS, ELVN, BGM, AMPH, SYRE, DYN, GPCR, RCUS, ARDX, and COLLShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Pharvaris (PHVS), Enliven Therapeutics (ELVN), BGM Group (BGM), Amphastar Pharmaceuticals (AMPH), Spyre Therapeutics (SYRE), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Arcus Biosciences (RCUS), Ardelyx (ARDX), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Its Competitors Pharvaris Enliven Therapeutics BGM Group Amphastar Pharmaceuticals Spyre Therapeutics Dyne Therapeutics Structure Therapeutics Arcus Biosciences Ardelyx Collegium Pharmaceutical Vor Biopharma (NASDAQ:VOR) and Pharvaris (NASDAQ:PHVS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment. Do analysts rate VOR or PHVS? Pharvaris has a consensus price target of $36.20, indicating a potential upside of 81.00%. Given Pharvaris' higher probable upside, analysts plainly believe Pharvaris is more favorable than Vor Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, VOR or PHVS? Pharvaris is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVor BiopharmaN/AN/AN/A-$1.51-1.39PharvarisN/AN/A-$145.24M-$3.01-6.64 Does the media favor VOR or PHVS? In the previous week, Pharvaris had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 3 mentions for Pharvaris and 1 mentions for Vor Biopharma. Pharvaris' average media sentiment score of 0.77 beat Vor Biopharma's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media. Company Overall Sentiment Vor Biopharma Neutral Pharvaris Positive Which has more risk & volatility, VOR or PHVS? Vor Biopharma has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.81, indicating that its share price is 381% less volatile than the S&P 500. Do insiders & institutionals believe in VOR or PHVS? 97.3% of Vor Biopharma shares are held by institutional investors. 2.9% of Vor Biopharma shares are held by insiders. Comparatively, 11.8% of Pharvaris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is VOR or PHVS more profitable? Vor Biopharma's return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Vor BiopharmaN/A N/A N/A Pharvaris N/A -54.02%-50.36% SummaryVor Biopharma beats Pharvaris on 8 of the 13 factors compared between the two stocks. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$262.14M$229.22M$2.21B$9.53BDividend YieldN/AN/A2.59%4.08%P/E Ratio-1.39N/A22.1423.80Price / SalesN/AN/A83.4188.08Price / CashN/AN/A26.0557.96Price / BookN/AN/A40.025.55Net IncomeN/AN/A-$62.28M$259.03M7 Day Performance-4.55%-13.67%-2.44%-4.56%1 Month Performance44.83%18.99%-0.52%4.49%1 Year PerformanceN/A142.77%26.20%18.05% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma0.2434 of 5 stars$2.10+1.4%N/AN/A$262.14MN/A-1.39140News CoverageShort Interest ↑Gap DownPHVSPharvaris1.706 of 5 stars$20.62+2.8%$36.20+75.6%+25.5%$1.08BN/A-6.8530High Trading VolumeELVNEnliven Therapeutics2.4421 of 5 stars$21.20-3.4%$41.20+94.3%-24.2%$1.08BN/A-11.0450BGMBGM GroupN/A$10.45-4.6%N/AN/A$1.06B$26.85M0.00298High Trading VolumeAMPHAmphastar Pharmaceuticals4.377 of 5 stars$22.37-0.6%$32.33+44.5%-50.0%$1.06B$731.97M8.112,028News CoverageUpcoming EarningsSYRESpyre Therapeutics2.2931 of 5 stars$17.79+1.1%$53.40+200.2%-39.6%$1.06BN/A-4.7273News CoveragePositive NewsUpcoming EarningsGap DownDYNDyne Therapeutics3.572 of 5 stars$9.95+7.7%$40.63+308.3%-76.1%$1.05BN/A-2.77100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGPCRStructure Therapeutics2.0331 of 5 stars$17.94-1.8%$76.17+324.6%-51.7%$1.05BN/A-20.62136News CoverageUpcoming EarningsRCUSArcus Biosciences2.1329 of 5 stars$10.21+3.4%$21.29+108.5%-41.8%$1.05B$258M-2.44500Upcoming EarningsARDXArdelyx4.1303 of 5 stars$4.29-1.6%$10.89+153.8%-21.3%$1.04B$333.61M-19.5090News CoverageUpcoming EarningsCOLLCollegium Pharmaceutical4.1095 of 5 stars$31.78-1.0%$43.75+37.7%-22.1%$1.03B$631.45M26.05210Upcoming Earnings Related Companies and Tools Related Companies PHVS Competitors ELVN Competitors BGM Competitors AMPH Competitors SYRE Competitors DYN Competitors GPCR Competitors RCUS Competitors ARDX Competitors COLL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VOR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VOR Stock Alerts